

Personalized Nutrient Interventions in the era of Precision Medicine

David H. Haase, MD, **CNS**, IFM-CP

doc@maxwellclinic.com

Acknowledgements:

- Jeff Bland, PhD
- Helen Messier, PhD, MD
- Sidney Baker, MD
- David Hagedorn, PhD
- David Cantor, PhD
- Lee Hood, MD, PhD
- Andy Braley PhD
- Richard Lord, PhD
- Stephen Hines, MD
- David Agerter, MD
- Terry Dermody, MD
- Mark Percival, ND, DC
- Gregory Kelly, ND
- Rex Cannon, PhD
- Kara Fitzgerald, ND
- Todd Lepine, MD

Faculty Disclosure

Commercial Interest	Nature of Relevant Financial Relationship (Include all those that apply)	
	What was received	For what role
• Xymogen	• Honoraria/ Shares	• Consultant
• BioCeuticals	• Honoraria	• Consultant

Presentation Learning Objectives

After participating in this presentation, learners should be better able to:

- Use precision medicine to provide insight in assessing toxicity and nutrient insufficiency
- Use data to identify mechanisms of toxic burden
- Employ nutrient interventions to reduce risk of toxicity.


Presentation Clinical Actions

After participating in this presentation, clinicians should be better able to:


- Recognize that while precision medicine as applied to nutrition has strengths, it also has some pitfalls and that as our knowledge evolves over the next years, so will its application in practice.

Pheno from
Greek 'phaino' = shining and
Greek 'phainein' = to show

Phenotype = How
we each show up
and shine




Creating Health...



That we may live as our Highest
Potential Phenotype

Constructome

Connectome



I think that I shall never see
A poem lovely as a tree.

A tree whose hungry mouth is prest
Against the earth's sweet flowing
breast;

A tree that looks at God all day,
And lifts her leafy arms to pray;

A tree that may in Summer wear
A nest of robins in her hair;

Upon whose bosom snow has lain;
Who intimately lives with rain.

Poems are made by fools like me,
But only God can make a tree.

-Joyce Kilmer























































Digging Deeper in Assessment



Genetic Origins of Individual Variations in Metabolism

More than 100 years ago, Archibald Garrod already suggested a link between *chemical individuality* and *predisposition to disease*.



INBORN ERRORS OF METABOLISM

By

ARCHIBALD E. GARROD, K.C.M.G.

D.M., LL.D., F.R.S., F.R.C.P.

*Regius Professor of Medicine in the University of Oxford
Consulting Physician to St. Bartholomew's Hospital
and to the Hospital for Sick Children*

First Edition 1909

'.....merely extreme examples of variations of chemical behaviour which are probably everywhere present in minor degrees' and that this 'chemical individuality [confers] predisposition to and immunities from the various mishaps which are spoken of as diseases'

-Archibald Garrod

A brief History of metabolomics

Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatography

(orthomolecular medicine/vitamins/controlled diet)

LINUS PAULING*, ARTHUR B. ROBINSON*, ROY TERANISHI†, AND PAUL CARY*

* Department of Chemistry, Stanford University, Stanford, California 94305; and † Western Regional Laboratory, U.S. Department of Agriculture

Contributed by Linus Pauling, July 28, 1971

Metabolomics

- **metabolomics developed by Pauling in 1970**
- **the term metabolomics first used in 1998**
 - **Oliver SG et al (1998). Trends Biotechnol 16:373**
- **Metabolomics Society founded 2004**
- **January 23rd, 2007 first draft of the human metabolome “completed”**

Examples of metabolites

- Peptides
- Oligonucleotides
- Sugars
- Nucleosides
- Organic acids
- Ketones
- aldehydes
- Amines
- Amino acids
- Lipids
- Steroids
- Alkaloids
- Drugs
- Xenobiotics

Complexity Of Metabolite Medicine

~200,000
compounds
theorized in human
biology

Little knowledge
about network
regulation

7 orders of
magnitude
dynamic range

Paucity of
normative
Databases

Diverse Chemistry,
No Amplification

Inadequate
Genome
annotation

No standards on
reporting or
publishing
metabolomic
patterns

Super Pathway	Sub Pathway ^	Biochemical Name	Fold Change								
			IDEP1	IDEP2	IDEP3	IDEP4	IDEP5	IDEP6	IDEP7	IDEP8	IDEP9
Amino Acid	Alanine and Aspart...	alanine	0.63	0.49	1.19	1.34	0.87	-1.74	-1.23	-1.13	-0.60
Amino Acid	Alanine and Aspart...	N-acetylalanine	1.83	0.62	-1.31	0.62	-0.36	-1.23	-1.59	1.03	0.34
Amino Acid	Alanine and Aspart...	aspartate	0.03	0.33	0.96	0.35	0.41	-0.42	1.58	-3.74	-0.76
Amino Acid	Alanine and Aspart...	asparagine	-2.15	2.17	0.09	-0.31	-0.04	0.18	-1.54	0.91	0.56
Amino Acid	Alanine and Aspart...	N-acetylaspargate (NAA)	3.14	-1.22	0.42	-0.54	-0.87	-0.78	0.54	0.92	-0.71
Carbohydrate	Aminosugar Metab...	glucuronate	0.63	0.52	-0.29	-0.45	-0.22	-1.34	-0.87	-0.49	4.28
Carbohydrate	Aminosugar Metab...	N-acetylneuraminate	0.80	0.92	-1.59	-1.11	-1.50	0.54	1.68	-0.39	0.52
Carbohydrate	Aminosugar Metab...	erythronate*	0.55	0.06	1.10	1.06	1.45	-1.13	-1.54	-1.60	-0.11
Cofactors and Vitamins	Ascorbate and Ald...	threonate	1.07	1.36	-0.91	-1.39	-1.33	1.00	1.18	-0.24	-0.72
Cofactors and Vitamins	Ascorbate and Ald...	oxalate (ethanedioate)	0.91	1.36	-1.47	-1.49	-0.96	0.88	1.27	-6.40E-3	-0.57
Cofactors and Vitamins	Ascorbate and Ald...	gulonic acid*	1.09	1.20	4.60E-3	-0.35	0.30	-1.24	-2.65	-0.18	1.29
Xenobiotics	Bacterial/Fungal	tartroate (hydroxymalonate)	1.42	1.33	-0.75	-0.42	1.13	-1.04	0.41	-0.11	-2.14
Xenobiotics	Benzoate Metaboli...	hippurate	-0.30	3.15	0.12	-0.40	-0.72	-1.52	-1.00	0.66	0.84
Xenobiotics	Benzoate Metaboli...	2-hydroxyhippurate (salicylurate)	-1.73	-0.89	-0.08	-0.32	-0.45	2.18	-0.64	0.76	1.51
Xenobiotics	Benzoate Metaboli...	3-hydroxyhippurate	0.38	3.10	0.31	0.25	-0.09	-1.27	-2.00	-0.41	0.28
Xenobiotics	Benzoate Metaboli...	4-hydroxyhippurate	-0.13	0.16	0.14	-0.50	3.15	0.32	-2.60	-0.56	0.36
Xenobiotics	Benzoate Metaboli...	benzoate	-0.67	0.49	0.25	1.14	-1.17	0.02	2.68	-0.85	-1.33
Xenobiotics	Benzoate Metaboli...	catechol sulfate	-0.32	4.00	-0.23	-0.28	-0.76	-0.16	-1.70	0.06	0.86
Xenobiotics	Benzoate Metaboli...	3-methylcatechol sulfate	-0.36	4.17	0.19	0.26	-0.54	-0.18	-1.74	-0.73	0.47
Xenobiotics	Benzoate Metaboli...	3-methylcatechol sulfate (1)	0.06	3.05	-0.58	-0.81	-0.71	-0.46	-0.27	-0.89	1.74
Xenobiotics	Benzoate Metaboli...	4-methylcatechol sulfate	1.85	1.93	-0.11	-0.21	-0.87	-1.76	-0.97	0.05	0.38
Xenobiotics	Benzoate Metaboli...	4-ethylphenylsulfate	1.85	0.67	-1.18	-1.13	-1.02	-0.86	0.11	1.71	0.15
Xenobiotics	Benzoate Metaboli...	4-vinylphenol sulfate	-0.86	0.60	0.57	0.35	0.30	1.34	0.83	-3.21	-0.91
Xenobiotics	Benzoate Metaboli...	4-sulfoxy-phenylbenzoate	1.41	-0.70	-1.22	-1.33	-1.20	1.09	1.50	0.25	0.26
Cofactors and Vitamins	Bifidobacterium	biotin	-0.35	-0.35	-0.35	-0.35	-0.35	0.00E0	-0.35	-0.35	-0.35
Lipid	Carnitine Metabolism	deoxycarnitine	-1.42	-0.90	1.20	1.95	1.32	-1.04	-0.58	-0.04	-0.18
Lipid	Carnitine Metabolism	carnitine	-0.18	0.29	1.38	1.84	0.44	0.15	-2.22	-1.18	-0.66
Xenobiotics	Chemical	1,2-propanediol	3.84	-0.77	0.13	-0.44	-0.38	-0.72	-0.57	-0.80	1.32
Xenobiotics	Chemical	2-pyrrolidinone	-0.22	-0.53	-1.22	-0.38	0.76	4.30	-0.94	-0.36	0.40
Xenobiotics	Chemical	sulfate*	2.37	-0.52	-0.42	1.10	0.87	-1.73	0.06	-0.22	-1.19
Xenobiotics	Chemical	O-sulfo-L-tyrosine	2.98	-0.82	-0.19	0.68	-0.56	0.13	-0.95	0.93	-1.46
Xenobiotics	Chemical	2-aminophenol sulfate	-3.11	0.14	1.08	0.85	0.61	1.18	-0.48	-0.06	-1.10
Xenobiotics	Chemical	2-ethylhexanoate	0.20	0.31	0.04	0.48	-0.84	3.37	0.01	-0.79	-1.99
Xenobiotics	Chemical	2-hydroxyisobutyrate	0.65	2.94	-0.92	-0.43	-0.33	-0.92	-0.83	1.37	-0.62
Xenobiotics	Chemical	4-(3-hydroxypropyl)mercapturic ...	0.23	-0.62	1.10	-0.62	-0.62	-0.62	-0.62	-0.62	4.37
Xenobiotics	Chemical	dimethyl sulfone	-0.35	0.05	-0.32	-0.62	-0.33	0.10	10.08	-0.83	-0.47
Xenobiotics	Chemical	EDTA	0.41	1.59	0.20	1.86	0.31	-0.37	-1.03	-1.35	-1.47
Xenobiotics	Chemical	glycolate (hydroxyacetate)	1.98	-0.80	0.29	1.06	-1.00	-2.10	0.85	-0.45	0.14
Xenobiotics	Chemical	imidodiacetate (IDA)	-0.29	-1.18	1.39	1.15	1.04	-0.91	1.11	-1.13	-1.09
Xenobiotics	Chemical	phenylcarnitine	-1.98	3.09	0.38	0.37	-0.66	-0.95	-0.38	0.24	0.49
Xenobiotics	Chemical	phenylethylsuccinate	2.79	0.23	0.53	0.48	0.48	-1.67	-1.23	-0.94	-0.22
Xenobiotics	Chemical	4-hydroxychlorothalonil	1.08	0.24	0.70	0.80	0.73	-3.47	-1.10	-0.55	0.34
Xenobiotics	Chemical	1,2,3-benzenetriol sulfate (2)	-0.70	1.37	0.58	0.14	-0.25	-0.42	-3.05	0.04	1.66
Xenobiotics	Chemical	3-hydroxypyridine sulfate	-0.82	2.23	-0.34	-0.38	-0.04	-0.57	-0.51	-1.05	2.45
Amino Acid	Creatine Metabolism	creatinine	1.45	-1.32	-0.58	-0.86	0.88	2.19	-0.32	0.03	-1.06
Amino Acid	Creatine Metabolism	creatinine	0.38	-0.41	1.50	1.47	1.10	-1.73	-1.32	-0.38	-0.59
Amino Acid	Creatine Metabolism	guanidinoacetate	-1.45	0.07	1.04	1.06	-3.28	-0.06	0.44	0.55	0.48
Peptide	Dipeptide	aspartylleucine	-0.38	1.03	-0.70	-0.23	0.70	-3.15	0.33	-0.10	1.80
Peptide	Dipeptide	cyclo(gly-pro)	0.56	1.21	0.77	0.73	0.77	-2.20	-1.86	-0.60	0.02
Peptide	Dipeptide	cyclo(leu-pro)	1.33	1.04	-0.13	-0.92	-0.99	-0.86	-0.14	-1.09	2.25
Peptide	Dipeptide	cyclo(leu-pro-D-pro)*	0.66	2.14	-0.73	-0.51	-0.73	-0.73	-0.73	-0.73	2.10

Heat Maps -

Need
Normative
Database

Or True

Quantitative
Measures


Identifying Hubs of Interest

Pathway	IDEP1	IDEP2	IDEP3	IDEP4	IDEP5	IDEP6	IDEP7	IDEP8	IDEP9
Tocopherol Metabolism	3.2	1	1	1	1	1.1	1	1	2.4
Tryptophan Metabolism	2.6	1	2.6	2.7	1	1.5	1.4	1	1.5
Pentose Metabolism	2.4	2	10.9	1	1	1	1	1	1
Leucine, Isoleucine and Valine Metab...	2.2	1.1	1	1.6	1	0.6	1.6	1.4	0.9
Purine Metabolism, (Hypo)Xanthine/I...	1.1	1	7.2	1	1	1	1	1.4	4.2
Sphingolipid Metabolism	1.1	1	1	1	4.5	3.5	1.3	1	1
Long Chain Fatty Acid	1	1	1	1	6.3	1	1	5.4	1
Polyunsaturated Fatty Acid (n3 and n6)	1	1	1	1	1.9	0.6	1	2.9	2.7
Benzoate Metabolism	1	3.3	1	1	1.1	0.7	2	0.7	1
Polypeptide	1	4.8	1	1	1	1	1	1	1.3
Medium Chain Fatty Acid	1	4	1	1	1	1.1	1	2	1
Urea cycle; Arginine and Proline Meta...	1	0.6	1	1	1	1	3.7	1	1.5
Dipeptide	0.9	2.6	1.6	1	1	1.2	1.7	1	1.1
Xanthine Metabolism	0.9	4.8	1	1	1	3.4	1	1	1
Lysolipid	0.6	1.1	0.6	1	0.3	1.6	0.8	1.7	1.1
Secondary Bile Acid Metabolism	0.5	0.6	6.2	3.3	1	0.6	1.7	0.6	0.5
Fatty Acid Metabolism(Acyl Carnitine)	0.5	1.7	3.1	1	5.8	2.4	1	1.2	1


Comparing 9 samples. - See the Forest AND the Trees™ Where to ZOOM IN?




Visualizing Data




Cluster Analysis - Comparing 9 samples. See the Forest AND the Trees™










Hubs of Interest



TCA cycle organic acid analysis, with cofactors. Where is the Defect?



Zoom in on CoQ10.



Normal FAD
Normal Fe⁺⁺


Normal CoQ10 by
Serum Testing..

Positive Resonse to
Supplementation

THE HUMAN MICROBIOME PROJECT SAYS THE HUMAN BODY HAS 100 TRILLION MICROSCOPIC LIFE FORMS LIVING IN IT.

YOU CALL THIS LIVING?

Frank Miller
© 2015
All Rights Reserved



Comprehensive Coverage of the Microbiome Metabolism

Metabolomic Microbiomics

(3-hydroxyphenyl)lactate
(4-hydroxyphenyl)pyruvate
4-hydroxyphenylacetate
3-hydroxyphenylacetate
3,4-dihydroxyphenylacetate
phenylacetylglutamine
phenylacetylglycine
2-(4-hydroxyphenyl)propionate
3-(3-hydroxyphenyl)propionate
3-(4-hydroxyphenyl)propionate
3-phenylpropionate
phenol sulfate
4-hydroxycinnamate
indolelactate
indoleacetate
indole-3-carboxylic acid
n-acetyltryptophan
3-indoxyl sulfate
indolepropionate
skatol
indoleacetylglutamine

Short chain FA:
valerate
Isovalerate
Methylpropionate
Lipids:
Lyso-PC, lyso-PE
Monacylglycerol
cholesterol

lipid metabolism

aromatic amino acid metabolism

lactate
formate,
succinate
glucose
urea
creatine
creatinine
ketoisovalerate


energy metabolism

cadaverine
putrescine
spermidine
spermine

polyamine metabolism

riboflavin
pyridoxine
folate

vitamins



bile acid metabolism

2nd bile acids:
cholate
dehydrocholate
ursodeoxycholate
deoxycholate
glycodeoxycholate
ketodeoxycholate
glycolithocholate sulfate
tauroolithocholate
tauroolithocholate sulfate
lithocholate
diketolithocholate
ketolithocholate
hyocholate
glycochenate sulfate
*taurochenate sulfate**
glycoursodeoxycholate
taoursodeoxycholate

xenobiotic metabolism

hippurate
2-hydroxyhippurate
3-hydroxyhippurate
4-hydroxyhippurate
3-hydroxybenzoate
4-hydroxybenzoate
3,4-dihydroxybenzoate
2,4,6-trihydroxybenzoate
p-hydroxybenzaldehyde
methyl-4-hydroxybenzoate
3-(2-hydroxyphenyl)propionate
vitexin
daidzein
genistein

choline metabolism

trimethylamine-n-oxide
betaine
dimethylglycine

exclusively or mainly contributed by bacteria metabolism
contributed by both mammalian cells and bacteria

Gut Bacteria Metabolism




Figure 4. Figure of gut microbial produced biochemicals, heat map of Z-scores where dark red and green are Z-scores are significant ($p < 0.05$) and light red and light green are Z-scores trending towards significant ($0.05 < p < 0.1$), along with box plots of associated biochemicals as described in **Figure 1**.

Dried Blood Spot Fatty Acid Profiles

Levels of Lipids

w-3

w-6

MUFA

Saturated FA

Trans-FA

Dried Blood Spot Fatty Acid Profile

Fatty Acid Group	Total	Percentile Rank	Reference Range*
Omega-3 Fatty Acids	6.56%	63 rd	2.92-13.29%
<i>Omega 3 Index</i>	6.22%	58 th	2.90-12.90%
<i>Alpha-Linolenic (18:3n3)</i>	0.68%		
<i>Eicosapentaenoic (EPA, 20:5n3)</i>	0.75%		
<i>Docosapentaenoic-n3 (22:5n3)</i>	1.57%		
<i>Docosahexaenoic (DHA, 22:6n3)</i>	3.56%		
Omega-6 Fatty Acids	38.20%	52 nd	26.35-45.15%
<i>Linoleic (18:2n6)</i>	24.41%		
<i>Gamma-Linolenic (18:3n6)</i>	0.28%		
<i>Eicosadienoic (20:2n6)</i>	0.31%		
<i>Dihomo-γ-linolenic (20:3n6)</i>	1.66%		
<i>Arachidonic (AA, 20:4n6)</i>	9.72%		
<i>Docosatetraenoic (22:4n6)</i>	1.45%		
<i>Docosapentaenoic-n6 (22:5n6)</i>	0.37%		
cis-Monounsaturated Fatty Acids	21.27%	51 st	15.65-32.26%
<i>Palmitoleic (16:1n7)</i>	0.47%		
<i>Oleic (18:1n9)</i>	19.28%		
<i>Eicosenoic (20:1n9)</i>	0.32%		
<i>Nervonic (24:1n9)</i>	1.20%		
Saturated Fatty Acids	33.43%	47 th	29.52-37.74%
<i>Myristic (14:0)</i>	0.40%		
<i>Palmitic (16:0)</i>	19.52%		
<i>Stearic (18:0)</i>	11.72%		
<i>Arachidic (20:0)</i>	0.22%		
<i>Behenic (22:0)</i>	0.70%		
<i>Lignoceric (24:0)</i>	0.87%		
Trans Fatty Acids	0.58%	5 th	0.35-2.69%
<i>Trans Palmitoleic (16:1n7t)</i>	0.10%		
<i>Trans Oleic (18:1t)</i>	0.32%		
<i>Trans Linoleic (18:2n6t)</i>	0.16%		
<i>Trans Fat Index</i>	0.48%	5 th	0.30-2.42%
Ratios			
<i>AA:EPA</i>	13.0:1	56 th	1.4 – 52.6
<i>Omega-6:Omega-3</i>	5.8:1	39 th	2.3 – 14.5

Lipomics

Lipomics

Patterns of Carnitine Metabolism

Levels of Lipids

Saturated

PUFA

w-3

w-6

w-9

MUFA

SCFA

MCFA

Trans-

VLCFA

Odd Chain


Renegades

Omega ox'd

	% Status	Result	Low	High
16 DMA	58.62 H	1.81	1.34	1.78
18:0 DMA	-11.20	2.83	2.55	3.26
18:1 DMA	50.00 H	1.07	0.74	1.07
C10:0 Capric	250.00 H	0.0080	0.002	0.004
C14:0 Myristic	-76.85 L	0.18	0.21	0.31
C14:1w5 Myristoleic	-50.00 L	0.0010	0.001	0.003
C15:0 Pentadecanoic	-87.21 L	0.07	0.09	0.13
C16:0 Palmitic	-102.79 L	17.41	18.54	20.69
C16:1w7 Palmitoleic	-49.06 L	0.09	0.09	0.20
C16:1w9 Hexadecanoic	-45.83 L	0.05	0.05	0.07
C17:0 Heptadecanoic	-60.00 L	0.28	0.29	0.38
C17:1 Heptadecaenoic	-25.00	0.02	0.02	0.03
C18:0 Stearic	-68.47 L	14.19	14.57	16.83
C18:1w5 Octadecanoic	-95.45 L	0.00	0.06	0.19
C18:1w7 Vaccenic	53.35 H	0.84	0.62	0.83
C18:1w9 Oleic	34.25 H	11.87	10.47	12.14
LA C18:2w6 Linoleic	9.03	9.46	7.73	10.65
C18:2w6 Conj Rumenic	-110.00 L	0.02	0.04	0.07
ALA C18:3w3 Alpha Linolenic	-31.25 L	0.09	0.07	0.14
GLA C18:3w6 Gamma Linolenic	92.11 H	0.05	0.02	0.04
C20:0 Arachidic	-71.28 L	0.34	0.36	0.46
C20:2w6 Eicosadienoic	13.33	0.25	0.19	0.28
DGLA C20:3w6 Dihomo-γ Lino.	37.02 H	1.49	0.99	1.56
C20:3w9 Mead	5.00	0.04	0.03	0.04
AA C20:4w6 Arachidonic	-8.88	11.87	10.77	13.31
EPA C20:5w3 Eicosapenta.	69.46 H	1.19	0.17	1.03
C22:0 Behenic	-83.42 L	1.38	1.51	1.90
C22:1w9 Erucic	0.00	0.05	0.04	0.06
C22:2w6 Docosadienoic	-46.67 L	0.05	0.05	0.08
C22:4w6 Adrenic	-3.71	2.42	1.88	3.04
C22:5w3 Docosapenta.	131.01 H	2.75	1.46	2.17
C22:5w6 Osbond	-56.01 L	0.34	0.36	0.74
DHA C22:6w3 Docosahexa.	65.33 H	5.02	2.70	4.71
C23:0 Tricosanoic	-90.00 L	0.23	0.26	0.33
C24:0 Lignoceric	-41.86 L	4.68	4.61	5.53
C24:1w9 Nervonic	167.05 H	5.48	3.23	4.27
C24:2w6 Tetracosadienoic	84.02 H	0.76	0.43	0.67
C25:0 Pentacosanoic	-46.77 L	0.10	0.09	0.13
C26:0 Hexacosanoic	-1.95	0.26	0.22	0.30
C26:1 Lumequic	31.82 H	0.26	0.17	0.27
C26:2 Hexacosadienoic	17.31	0.14	0.07	0.17
C28:0 Octacosanoic	-50.00 L	0.0030	0.003	0.005
C30:0 Triacontanoic	50.00 H	0.0010	0.000	0.001
Phytanic	0.00	0.0020	0.001	0.003
Pristanic	950.00 H	0.0010	0.000	0.000
Sum C16:1 Trans FAs	-108.06 L	0.02	0.04	0.07
Sum C18:1 Trans FAs	-95.83 L	0.21	0.47	1.03
Sum C18:2 Trans FAs	-84.00 L	0.06	0.07	0.12

Genomics

Whole Genome Analysis



Humans have approximately 10 trillion cells
If you were to line all of the DNA found in every
cell of a human body it would stretch from the
earth to the sun 100 times!



SNV's

- 6 Billion Nucleotides - we sequence ~85%
- SNV's occur one in every 300 nucleotides
- Approximately 20 million in the human genome
- 8000 unique to each person
- If in a exon or regulatory region of a gene can affect the gene function

- Most are Variants of Unknown Significance
- SNPs are SNVs that have >1% prevalence

Whole Genome Analysis


Variant Statistics

	SNVs	Deletions	Insertions
Total Number	3,507,174	271,870	276,245
Number in Genes	1,346,666	116,847	118,650
Number in Exons	47,010	2,898	3,137
Number in Coding Regions	19,759	235	275
Number in UTR	27,251	2,663	2,862
Splice Site Region	2,483	193	216
Stop Gained	79	0	0
Stop Lost	31	0	0
Frameshift	0	111	152
Non-synonymous	10,470	4	7
Synonymous	9,278	0	0



Copy Number Variation

- Accounts for more variation than SNP's
- Deletions, inversions, insertions, and duplications
- 0.4% of the genomes of unrelated people differ with respect to copy number variation
- May be inherited or arise during development
- Variable number of tandem repeats
 - Found throughout genome and show variations in length even between related individuals

Copy Number Variation




Chromosomal Instability score from CNV Genomics as a Cancer Marker



- **Second Opinion™ Validation Study published in high impact January 2015 Special Issue “Molecular Diagnostics: A Revolution in Progress”**


Tumor Load Liquid Biopsy via Copy Number Instability (CNI)

- Circos Plot
 - Red = gain
 - Blue = loss
- Inner circle - PBMC CNI
- Middle Circle - Cell Free DNA CNI (unadjusted)
- Outer Circle - CNI remaining after adjustment for PBMC



Tumor Load Liquid Biopsy via CNI

- CNI = Copy Number Instability
- Widely Metastatic Triple Negative Breast Cancer




Examples of the role and the effect of deficiency of specific micronutrients on genomic stability

Micronutrients	Role in genomic stability	Consequence of deficiency
Vitamin C, vitamin E	Prevention of oxidation to DNA and lipid oxidation (157,158)	Increased baseline level of DNA strand breaks, chromosome breaks and oxidative DNA lesions and lipid peroxide adducts on DNA (157,158)
Folate and vitamins B2, B6 and B12	Maintenance methylation of DNA; synthesis of dTMP from dUMP and efficient recycling of folate (24)	Uracil misincorporation in DNA, increased chromosome breaks and DNA hypomethylation (24)
Niacin	Required as substrate for poly(ADP-ribose) polymerase (PARP) which is involved in cleavage and rejoining of DNA and telomere length maintenance (61,159)	Increased level of unrepaired nicks in DNA, increased chromosome breaks and rearrangements, and sensitivity to mutagens (61,159)
Zinc	Required as a cofactor for Cu/Zn superoxide dismutase, endonuclease IV, function of p53, Fapy glycosylase and in Zn finger proteins such as PARP (27,28)	Increased DNA oxidation, DNA breaks and elevated chromosome damage rate (27,28)
Iron	Required as component of ribonucleotide reductase and mitochondrial cytochromes (160)	Reduced DNA repair capacity and increased propensity for oxidative damage to mitochondrial DNA (160)
Magnesium	Required as cofactor for a variety of DNA polymerases, in nucleotide excision repair, base excision repair and mismatch repair. Essential for microtubule polymerization and chromosome segregation (50)	Reduced fidelity of DNA replication. Reduced DNA repair capacity. Chromosome segregation errors (50)
Manganese	Required as a component of mitochondrial Mn superoxide dismutase (152,161)	Increase susceptibility to superoxide damage to mitochondrial DNA and reduced resistance to radiation-induced damage to nuclear DNA (152,161)


Tumor Load Liquid Biopsy via CNI

- Colon Cancer – Stage 2 before resection, Chemo, Nutrition Rx.
- BRCA1 loss
- Curcumin,
- 3-6 Beta Glucan,
- w-3 oils,
- WGE- whole glucan extract



Tumor Load Liquid Biopsy via CNI

- Colon Cancer – Stage 2 after resection, chemo, Nutrition Rx.
- CNI down from 1363 to 19.



Clinical Presentation:

- 55 yo male CEO –
- Fatigue, Exercise Intolerance, Brain Fog, Joint Pain, Irritability, Insomnia, Hyperlipidemia
- PastDx: Hashi, Arthritis, Asthma
- FHx: M-Lung Cancer; F – Dementia
- Organic whole-food, gluten & dairy-free diet, Meditates, 10 hrs in Bed (!!!), Exercises as best as possible, Low Caffeine, Stable relationships, Has hobbies and positive mindset.
- Elevated Liver Enzymes- but why?

23&Me derivative “Detox” Report

GSTP1 I105V	rs1695	AA	-/-
GSTP1 A114V	rs1138272	CC	-/-
SOD2 A16V	rs4880	GG	+/+
NAT1 R187Q	rs4986782	GG	-/-
NAT1 R64W	rs1805158	CC	-/-
NAT2 I114T	rs1801280	CT	+/-
NAT2 R197Q	rs1799930	GG	-/-
NAT2 G286E	rs1799931	GG	-/-
NAT2 R64Q	rs1801279	GG	-/-
NAT2 K268R	rs1208	AG	+/-

Gene	Result
GSTT1	Present

And no GSTM data


Copy Number Variations

Gain/Loss	CytoBand	Location	Size (bp)	# Probes	Ratio	Genes
LOSS	1q44	chr1:248756215-248790932	34,717	6	0.58	OR2T10, OR2T11
LOSS	3q26.1	chr3:162514534-162619141	104,607	13	0.61	
LOSS	4q13.2	chr4:69360187-69512319	152,132	31	0.78	TMPRSS11E, UGT2B17, UGT2B15
LOSS	5p15.33	chr5:702100-820424	118,324	14	0.59	ZDHHC11
LOSS	5p15.2	chr5:12677352-12735332	57,980	6	0.53	
LOSS	6p21.32	chr6:32485374-32551409	66,035	15	0.65	HLA-DRB5, HLA-DRB6, HLA-DRB1
GAIN	8p23.1	chr8:6639145-6949625	310,480	35	1.43	XKR5, DEFB1, DEFA6, DEFA4, DEFA10P, DEFA1, DEFA1B, DEFA3, DEFA5
LOSS	8p11.22	chr8:39233204-39371728	138,524	26	0.74	ADAM5P, ADAM3A
LOSS	9p23	chr9:12031727-12163289	131,562	14	0.53	
GAIN	11q13.2	chr11:67479305-67750341	271,036	20	1.23	LOC645332
LOSS	12p13.31	chr12:9637084-9713425	76,341	9	0.44	
LOSS	15q11.1 - q11.2	chr15:20549990-22589756	2,039,766	82	0.75	GOLGA6L6, GOLGA8C, BCL8, POTE, NF1P1, LOC646214, CXADRP2, LOC727924, OR4M2, OR4N4, OR4N3P
GAIN	16p11.2 - p11.1	chr16:34468000-34756866	288,866	39	1.83	LOC283914, LOC146481
GAIN	21p11.2 - p11.1	chr21:10751620-10916406	164,786	17	1.32	TPTE
LOSS	22q11.23	chr22:24347959-24395353	47,394	17	0.36	LOC391322, GSTT1, GSTTP2

- Copy Number Variation Analysis revealed LOSS of GSTT1
- Targeted SNP testing revealed NULL GSTM

Markedly Elevated Aflatoxin IgG+IgA

TEST	RESULT			
	IN RANGE (Normal)	EQUIVOCAL*	OUT OF RANGE	REFERENCE (ELISA Index)
Array 11 Chemical Immune Reactivity Screen				
Aflatoxins IgG+IgA			2.69	0.4-1.8
Aflatoxins IgM	1.14			0.1-1.9
Formaldehyde and Glutaraldehyde IgG+IgA	0.72			0.3-1.4
Formaldehyde and Glutaraldehyde IgM	0.91			0.1-1.8
Isocyanate IgG+IgA	0.70			0.1-1.1
Isocyanate IgM	0.85			0.1-1.2
Trimellitic and Phthalic Anhydrides IgG+IgA	0.63			0.1-1.3
Trimellitic and Phthalic Anhydrides IgM	0.92			0.1-2.0
Benzene Ring Compounds IgG+IgA	0.65			0.2-1.3
Benzene Ring Compounds IgM	0.80			0.1-1.6
BPA Binding Protein IgG+IgA	0.87			0.2-1.8
BPA Binding Protein IgM	1.04			0.1-1.8
Bisphenol A IgG+IgA	0.66			0.1-1.8
Bisphenol A IgM	0.88			0.1-2.0
Tetrabromobisphenol A IgG+IgA	0.74			
Tetrabromobisphenol A IgM	0.65			
Tetrachloroethylene IgG+IgA	0.79			
Tetrachloroethylene IgM	1.90			




Aspergillus



Metabolomics of *Aspergillus fumigatus*

Spinulosin
 Spinulosin hydrate
 Spinulosin quinol-hydrat
 Dihydrospinulosin quino
 Phyllostine
 Orsellinic acid
 Orcinol
 m-cresol
 3,4-dihydroxytoluquinone
 4-hydroxy-3-methoxytoluquinone
 3-hydroxytoluquinone
 3,6-dihydroxytoluquinone
 3-hydroxy-4-methoxy-
 Toluquinone 1,6-epoxide
 4-carboxy-5,5'-dihydroxy-3,3'-dimethyldiphenyl
 Fumiquinone A
 Fumiquinone B
 Trypaclin
 Bisdechlorogedin
 Monomethylsulochrin
 Sulochrin-2'-methylether
 Asperfumin
 Asperfumoid
 Emodin
 Physcion
 2-chloroemodin
 2-chloro-1,3,8-trihydroxy-
 6-methylanthrone
 2-chloro-1,3,8-trihydroxy-
 6-hydroxymethylanthrone
 YWA1
 1,3,6,8-THN
 Flaviolin
 Scytalone
 1,3,8-THN
 2-HJ
 Vermelone
 1,8-DHN
 Sphingofungin A-D
 Sphingofungins E-F?
 Fumifungin
 Pseurotin A-E
 8-O-demethylpseurotin A
 Synerazol
 RK-95113
 Azaspirene?
 FD-839
 Pseurotin F2
 Ergosterol
 Ergosterolperoxide
 Ergosterolpalmitat
 24-methylenophenol
 Ergosta-4,6,8(14),22-tetraen-3-one
 Ergosta-4,22-diene-3 β -ol 5 α ,8 α -Epidioxy-ergosta-
 6,22-diene-3 β -ol
 Helvolic acid
 Helvolinic acid
 7-desacetoxylhelvolic acid





5-Demethoxyfumagillol
 Fumagiringillin
 FR-111142
 Sch528647
 RK-95113
 Ovalicin?
 β -*trans*-bergamotene
 Hexahydrodiprenyls A-E
 Phthioic acid
 Teichoic acid
 bis(2-hydroxy-3-tert. butyl-5-
 Methylphenyl)methane
 (= GERI-BP002-A)
 Fusigen
 Ferrichrome
 Gliotoxin
 Gliotoxin E
 Gliotoxin G
 S-methylgliotoxin
 bisdithiobis(methylthio)-
 Gliotoxin
 Agroclavine
 Elymoclavine
 Chanoclavine I
 Festuclavin
 Fumigaclavine A-C
 Brevianamide F
 Fumitremogin A-C
 Verruculogen
 15-acetoxyverruculogen
 Demethoxyfumitremogin C
 12,13-dihydroxyfumitremogin C (= TR-3)
 12,13-dihydrofumitremogin C
 TR-2
 Cyclotryprostatin A-D
 Dehydrotryprostatin
 Tryprostatin A & B
 Spirotryprostatin A & B
 'Compound 6'
 Alanyl-leucyl and alanyl-isoleucyl, prolyl-phenyl-
 lalanyl, prolyl-glycyl, prolyl-prolyl, prolyl-valyl, 4-
 hydroxyprolyl-leucyl, 4-hydroxyprolyl-phenylalanyl,
 and prolyl-leucyl diketopirazines
 Pypripropene A-R
 GERI-BP001-A
 Fumiquinazoline A-G
 Tryptoquivaline?
 Nortryptoquivaline?
 Tryptoquivaline E-N?


Metabolic signatures are possible to elucidate via metabolomics - this guides diagnostic as well as treatment decisions.

Aflatoxin B1 (2,3-Epoxyaflatoxin B1)

Conversion is by
CYP-1A2 and
CYP-3A4 and
CYP-2A13



Glutathione Congugates to Electrophilic Substrates via GSTT1



More “Good Stuff”



- **Sulforaphane**
 - Upregulates NRF-2 and PGC-alpha. This in turn...
- increases
 - Superoxide dismutase
 - Catalase
 - **glutathione S-transferase**
 - expression of heme oxygenase-1
- reduces
 - reactive oxygen species
 - lipid peroxidation
 - COX-2 expression

Effects of airborne *Aspergillus* on serum aflatoxin B₁ and liver enzymes in workers handling wheat flour

A Saad-Hussein¹, MM Taha¹, NN Fadl², A-H Awad³,
H Mahdy-Abdallah¹, G Moubarz^{1,4}, H Aziz¹ and KA El-Shamy²




Table 2. Comparison of the AFB₁-Alb levels and the liver enzymes between the milling workers, the bakers, and their controls.

	Controls (100)		Milling workers (100)		Bakers (90)		ANOVA
	Mean	SD	Mean	SD	Mean	SD	p Value
AFB ₁ -Alb (ng/g)	0.04 ^{a,b}	0.008	0.06 ^c	0.003	0.10	0.01	p < 0.0001
Liver enzymes							
AST (U/L)	16.2 ^{a,b}	10.9	26.5	8.70	26.0	8.33	p < 0.05
ALT (U/L)	18.2 ^{a,b}	7.56	37.5	10.66	37.6	11.14	p < 0.0001
ALP (IU/L)	77.4 ^b	24.50	76.7 ^c	25.71	90.0	32.11	p = .05


LSD: least significant difference; AFB₁: aflatoxin B₁; Alb: albumin; ANOVA: analysis of variance; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase.

^aAccording to LSD, significant difference between the controls and the milling workers.

^bAccording to LSD, significant difference the controls and the bakers.

^cAccording to LSD, significant difference between the milling workers and the bakers.

Glucomannan



- In rats fed high fat diet - KGM beneficially reduced
 - malondialdehyde levels of the colon and liver
 - DNA damage in blood lymphocytes
- Upregulated gene expressions of
 - colonic mucosa glutathione peroxidase and catalase
 - hepatic superoxide dismutase and catalase

Effect of Glucomannan on Mycotoxins

- Effect of glucomannan on haematological, coagulation and biochemical parameters in male rabbits fed aflatoxin-contaminated ration. –

» A. Eisa and A Metwally - World Mycotoxin Journal 2011

– Human studies of this would be unethical

– 3 groups

- Normal Chow
- Chow spiked with naturally occurring levels of aflatoxin
- Spiked chow with 1kg/ton glucomannan

Effect of glucomannan on Mycotoxins

- Results..
 - Aflatoxin B1 (AFB1) spiked chow caused microcytic anemia, leukopenia, long PT and aPTT, elevated ALT, GGT, Total Bilirubin, BUN, Creatinine, total lipids and cholesterol. Decreased Protein, Albumin, glucose, calcium, phosphorous, and iron.
- Supplementation with glucomannan resulted in the return of the above parameters to normal control values.


Glucomannan and Aflatoxin B1 and T-2 Toxin

- 0.1% Glucomannan in feed was able to adsorb
 - 75-90% of Aflatoxin (Aspergillus)
 - 30-35% of T2 Toxin (fusarium)
- The longer time Glucomannan was present in the gut, the more Mold Toxins were adsorbed.

Less “Bad Stuff”



Murthy, et. al. “Evaluation of glucomannan for its adsorbing ability of Aflatoxin B1 and T-2 Toxin in the gastrointestinal tract of boiler chickens” Mycotoxin research, Volume: 18 Issue: Supplement 1, 2002 March.



"Susan"

Since ~~2008~~²⁰⁰⁹, I have had chronic fatigue, pain and brain fog, neuropathy and weakness. I have been to a large amount of specialist who do not communicate with each other and only prescribe more

~~_____~~ I struggled for all of these years with sugar. I have hypoglycemia. I ~~lost~~ lost my will to live in December as I felt my quality of life was so poor and there was little or no hope of improving. ~~_____~~

“Susan”- Outside MD Note

History of Present Illness:

History of Present Illness provided by patient.

Abdominal pain over the past 9 years. 5 hospitalizations in 2015. GI consultant felt that this is going to be a recurrent situation over the rest of her life. Attributed to damage from cancer treatment. After meditation, prayer and reflection she went to [REDACTED] and was advised to see psychologist to deal with PTSD and work on diet and yoga. She is eating very healthily. Daily wakes with feeling of being hung-over: - dizziness, light-headedness, fatigue, dread, nausea with occasional vomiting, dehydration feeling. Persistent constipation - she has now increased her [REDACTED] natural laxative) - 8 per day reliably results in daily BM. Dr. [REDACTED] suggested getting another opinion - EGD with gastritis and colonoscopy with internal hemorrhoids.

Using CPAP nightly with good benefit. Tired of quality of life.

Feels that Savella is helping with fibromyalgia pain. Brain function better with Savella compared to Cymbalta.



Botox shots for migraines from Dr. [REDACTED] seem to help

Tramadol helps with pain without causing sedation or disorientation.


- Tx: Tylenol, Tramadol, Miralax

3590H1	CK	213	+ U/1	< 170	[.]	*>
3591H1	CKMB	37	+ U/1	< 25	[.]	*>

Mito Genetics – The Basics




Mitochondrial DNA



- 37 genes
- 16,000 base pairs
- Maternal inheritance
- 13 proteins for OxPhosphorylation
- 22 transfer RNAs
- 2 ribosomal RNAs

Nuclear DNA



- 1,013 genes
- Autosomal recessive
- Autosomal dominant
- X-linked



Contents lists available at [ScienceDirect](#)

Mitochondrion

journal homepage: www.elsevier.com/locate/mito




Hurt, tired and queasy: Specific variants in the ATPase domain of the *TRAP1* mitochondrial chaperone are associated with common, chronic “functional” symptomatology including pain, fatigue and gastrointestinal dysmotility



Richard G. Boles ^{a,*}, Holly A. Hornung ^a, Alastair E. Moody ^a, Thomas B. Ortiz ^a, Stacey A. Wong ^a, Julie M. Eggington ^a, Christine M. Stanley ^a, Mu Gao ^b, Hongyi Zhou ^b, Stephen McLaughlin ^a, Amir S. Zare ^a, Katherine M. Sheldon ^a, Jeffrey Skolnick ^b, Kevin J. McKernan ^a

TRAP1-Related Disease (*T1ReD*)

- *TRAP1* encodes a 701-amino acid homodimer protein which is a **mitochondrial chaperone** involved in antioxidant defense.
- An **ATPase domain** (amino acids 108-260) hydrolyze the energy-rich triphosphate bond of ATP to convert into mechanical work of folding proteins.



TRAP1-Related Disease (*T1ReD*)

- Chronic pain, Fatigue and GI dysmotility.
- Tachycardia/palpitations and dizziness may also be common.
- In these patients, chronic pain and fatigue improved greatly on aggressive antioxidant therapy.

TRAP1 variants greatly increase the prevalence of functional disease

<i>TRAP1</i> variants	Pain syndromes	Chronic fatigue	Gastro-intestinal dysmotility	Triad of pain, fatigue & GI	Total number of patients
All conserved in ATPase domain	17 (65%) 4.9 (2.2-11) P = 0.001	16 (62%) 3.3 (1.5-7.3) P = 0.004	14 (54%) 3.1 (1.4-6.8) P = 0.005	12 (46%) 6.4 (2.9-14) P < 0.0001	26
Conserved elsewhere in protein	3 (7%) 0.19 (0.06-0.61) P = 0.005	10 (22%)	11 (24%)	2 (4%)	45
p.Ile253Val	11 (69%) 5.7 (2.0-17) P = 0.001	10 (63%) 3.4 (1.2-9.4) P = 0.02	9 (56%) 3.4 (1.2-9.2) P = 0.02	8 (50%) 7.5 (2.8-20) P = 0.0001	16
Conserved in ATPase excluding p.Ile253Val	7 (64%) 4.6 (1.3-1.6) P = 0.02	7 (64%) 3.6 (1.0-1.2) P = 0.04	6 (55%) P = 0.06	5 (45%) 6.2 (1.9-21) P = 0.003	11
Salt bridges: p.Arg128His, p.Glu192Lys	5 (71%) 6.5 (1.3-34) P = 0.03	5 (71%) P = 0.053	5 (71%) 6.6 (1.3-34) P = 0.02	5 (71%) 18 (3.6-100) P = 0.0005	7
None	224 (28%)	266 (33%)	222 (27%)	95 (12%)	808

“Susan” TRAP-1 Hetero

TRAP1 - TNF RECEPTOR-ASSOCIATED PROTEIN 1, NM_016292.2 (OMIM® ID: 606219)

Variant 1 (chr16.hg19.g.3740911G>A) c.164C>T p.Ala55Val **Heterozygous** ACMG score 3

Interpretation One variant of uncertain significance was identified in this gene. This gene is associated with autosomal recessive and autosomal dominant disease. Clinical correlation is indicated.

Associated disease *TRAP1-Related Disease (T1ReD)*

Disease inheritance **Autosomal Dominant or Autosomal Recessive**

Associated literature PMID [10652318](#)

Gene product/protein function HSP90 proteins are highly conserved molecular chaperones that have key roles in signal transduction, protein folding, protein degradation, and morphologic evolution. HSP90 proteins normally associate with other cochaperones and play important roles in folding newly synthesized proteins or stabilizing and refolding denatured proteins after stress. TRAP1 is a mitochondrial HSP90 protein.

Variant 1 Classification **Variant of uncertain significance** *Prevalence:* Rare (0.00% in 1000G; 0.01% in ESP6500 (max subpopulation freq: 0.01%); 0.00% in ExAC (max subpopulation freq: 0.01%)); *Evolutionary Conservation:* Low; *Algorithms of protein function:* SIFT: equivocal, Mutationassessor: benign, Polyphen2: benign, MutationTaster: deleterious

DNA Oxidation Marker: 8-OH DG and Elevated CK in “Susan”

3590H1	CK	213	+ U/1	< 170	[..... *>
3591H1	CKMB	37	+ U/1	< 25	[..... *>

Oxidative Damage and Antioxidant Markers (Vitamin C and other antioxidants)



- Context: Organic, “Ideal” diet.
- Tx:
 - Sulphoraphane Glucosinolate, Resveratrol, Curcumin, - All High dose
 - NAC 1200 BID, ALA- 600 mg BID, CoQ10 50mg BID



8-OHDG Follow-up “Susan”

Oxidative Damage and Antioxidant Markers (Vitamin C and other antioxidants)

(Vitamin C and other antioxidants)

28. p-Hydroxyphenyllactate

0.11



≤ 0.66

29. 8-Hydroxy-2-deoxyguanosine

6.4

H



≤ 7.6

(Units for 8-hydroxy-2-deoxyguanosine are ng/mg creatinine)

Oxidative Damage and Antioxidant Markers (Vitamin C and other antioxidants)

(Vitamin C and other antioxidants)

28. p-Hydroxyphenyllactate

0.09



≤ 0.66

29. 8-Hydroxy-2-deoxyguanosine

2.4



≤ 7.6


(Units for 8-hydroxy-2-deoxyguanosine are ng/mg creatinine)

- Subsequent to this... 50 gm IV vitamin C twice a week has been very helpful.

Metabolomics Tools for Describing Complex Pesticide Exposure in Pregnant Women in Brittany (France)


Toxomics

Cereal_Group_PW11_OSC-PAR8.M1 (PLS-DA), PAR
 $w^*c[Comp.1]w^*c[Comp.2]$
Colored according to model terms



MATERNAL'S PESTICIDE EXPOSURE

Self-protective mechanisms



Integrated ^1H NMR-based metabolomics analysis of earthworm responses to sub-lethal Pb exposure

Ting Chen ^A, Yan Liu ^A, Ming-Hui Li ^A, Hua-Dong Xu ^A, Ji-Yang Sheng ^A, Li Zhang ^{A B} and Jun-Song Wang ^{A B}

^A Centre for Molecular Metabolism, School of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing 210094, China.

^B Corresponding authors. Email: wang.junsong@gmail.com; njust_zhangli@163.com

Environmental Chemistry - <http://dx.doi.org/10.1071/EN15192>


Submitted: 16 September 2015 Accepted: 5 February 2016 Published online: 23 March 2016

... “Pb exposure in earthworms caused widespread metabolic changes, which were associated with oxidative stress, neurotransmitter imbalance, disruption of osmotic equilibrium and interference in energy metabolism and nucleic acid metabolism.”

Table 1. Metabolites identified from the aqueous earthworm tissue extracts, their fold change values (control v. low, control v. medium and control v. high) and associated *P* values


HEFS, 2-hexyl-5-ethyl-3-furansulfonate; GABA, 4-aminobutyrate. Multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Colour coded according to $\log_2(\text{fold change value})$, red for decrease and blue for increase in Pb-exposed groups. *, *P* < 0.05; **, *P* < 0.01; ***, *P* < 0.001

Metabolites	Assignments	Chemical shift (ppm)	Control v. low		Control v. medium		Control v. high	
			Fold	<i>P</i>	Fold	<i>P</i>	Fold	<i>P</i>
HEFS		0.85 (t), 2.60 (m), 2.83 (t)	0.92		0.80	*	0.57	**
Leucine	δ-CH ₃ , δ-CH ₃	0.95 (d), 0.96 (d)	1.05		1.11	*	1.99	***
Isoleucine	δ-CH ₃ , γ-CH ₃	0.94 (t), 1.00 (d)	1.09	*	1.16	*	1.76	***
Valine	γ-CH ₃ , γ-CH ₃	0.98 (d), 1.04 (d)	1.06		1.21	**	1.64	***
Lactate	CH ₃	1.43 (d)	1.04		1.06		1.25	**
Lysine	CH ₂	1.71 (m)	1.06		1.16	*	1.24	**
GABA	CH ₂	1.91 (m)	0.94		1.12	*	1.18	*
Glutamate	CH ₂	2.05 (m)	1.07		1.09	*	1.26	**
Glutamine	CH ₂	2.14 (m)	1.05		1.06		1.13	*
Methionine	CH ₂	2.13 (m)	1.08	*	1.16	*	1.69	**
Choline	CH ₃	3.20 (s)	1.09	*	1.24	*	2.91	***
Phosphocholine	CH ₃	3.21 (s)	1.08	*	1.16	*	1.22	**
Betaine	CH ₂ , CH ₃	3.25 (s), 3.89 (s)	1.07		1.27	**	1.90	***
Dimethylglycine	CH ₂	3.71 (s)	1.05		0.99		1.13	*
Serine	CH ₂	3.95 (m)	0.93		0.89	*	0.75	**
<i>myo</i> -Inositol	CH	3.54 (dd), 3.63 (t), 4.07 (t)	0.84	*	0.74	**	0.47	***
Glucose		3.45–3.50 (m), 4.65 (d)	1.10	*	1.29	*	1.73	***
Maltose	CH	5.41 (d)	0.91	*	0.88	*	0.89	*
Tyrosine	–CH=	6.90 (m), 7.20 (m)	1.05	*	1.18	**	1.21	**
Phenylalanine	CH=CH	7.33 (d), 7.38 (m), 7.43 (m)	1.12	*	1.20	**	1.33	**
Tryptophan	Ar-H	7.53 (d), 7.73 (d)	1.06		1.15	*	1.35	**
Inosine	O-CH-N, N-CH-N	6.90 (m), 7.20 (m)	1.09	*	1.07		1.18	*



Effects of Lead on Metabolomics (earthworm)

Toxomics meets
Metabolomics



Metabolomics Reveals that Aryl Hydrocarbon Receptor Activation by Environmental Chemicals (dioxin-like) Induces Systemic Metabolic Dysfunction in Mice

Zhang, Environ. Sci. Technol. 29 May 2015

Toxomics meets Metabolomics



Blood

Lipid, LDL/VLDL, HDL, UFA, Alanine

transportation

Liver

Fatty acid Synthesis & Biotransformation



Mitochondria

Lipid/UFA
Lipogenesis

Acetyl-CoA

Lactate

Glycogen

Glycogenolysis

Pyruvate

G6pase, Gut2, Pepck

Glucose

Gluconeogenesis

Alanine

Inflammation

PC, GPC, Phospholipid


Cell membrane

Lcn2, IL-1 β , TNF- α , Saa1 (Ileum), NAG, OAG (serum)


Cyp1a1

Xenobiotic response


Connectomics



2 weeks



1 year



2 years



2 weeks



1 year




Adult






HOMEOSTATIC EEG REGULATORY SYSTEM

▶ = EXOGENOUS SPECIFIC INPUT
 ▶ = NONSPECIFIC PROCESSING
 ▶ = ENDOGENOUS READOUT
 ▶ = INHIBITORY INFLUENCES




Connectomics






This patient's discriminant scores lie within ($p \leq 0.025$) of the normal limits expected for an individual of this age.

Heart Rate Variability



Neuro-Cardiac Stability	Patient Score	Normal Range
Heart Rate (bpm)	73	55-80
QTc interval	426.7	male < 440 ms female < 460 ms
QRS duration	0.092	0.06 - 0.12 sec

Autonomic Balance	Patient Score	Normal Range
Autonomic Balance (SDNN (ms))	70.25	75-150
Total Power	3394.9	>2000
Very Low Frequency (ms ²)	443.7	low
Low Frequency (ms ²)	2625.2	highest
High Frequency (ms ²)	326.0	low




Event Related Potentials




BRAIN PROCESSING SPEED

ERP Component	Amplitude and Latency	Patient Score	Suggested Range
Visual processing		212 ms -12.9 uV	< 250ms
Auditory processing		180 ms -19.5 uV	< 250ms
Attention/Vigilance		344 ms 13.5 uV	< 450ms
Information processing / Working memory		400 ms 5.6 uV	< 450ms


Brain Surface Maps



LORETA Brain Imaging



Volumetric 3-D LORETA



This tool can be expanded for use as a real time monitoring device for any intervention that may influence brain function

Three dimensional axial imagery allows high level of specificity in locating brain abnormalities

Brodmann Areas 22, 40, 42 are nearly 2 standard deviations low power from normal.


BRAIN FUNCTION: Standard Deviations - Normative database comparison

Severity Eyes Closed

	Pre-Frontal		Frontal					Central			Temporal		Parietal					Occipital	
	Fp1	Fp2	F7	F3	FZ	F4	F8	C3	CZ	C4	T7	T8	P7	P3	PZ	P4	P8	O1	O2
2Hz	-0.2	-0.1	-0.1	-0.3	-0.4	-0.3	-0.3	-0.5	-0.5	-0.5	-0.5	-0.7	-0.7	-0.6	-0.5	-0.7	-0.9	-0.9	-0.9
3Hz	-0.2	-0.1	-0.0	-0.3	-0.3	-0.3	-0.2	-0.3	-0.4	-0.4	-0.4	-0.6	-0.6	-0.5	-0.5	-0.6	-0.8	-0.8	-0.8
4Hz	-0.7	-0.5	-0.3	-0.9	-0.8	-0.7	-0.6	-0.7	-0.6	-0.7	-0.6	-0.8	-0.9	-0.7	-0.7	-0.8	-1.0	-1.0	-1.0
5Hz	-1.0	-1.0	-0.5	-1.1	-1.1	-1.1	-1.0	-0.8	-0.6	-0.8	-0.7	-1.0	-1.0	-0.9	-0.8	-0.9	-1.1	-1.1	-1.1
6Hz	-0.9	-0.9	-0.7	-1.1	-1.2	-1.1	-1.0	-1.1	-1.1	-1.0	-0.7	-1.0	-1.0	-1.1	-0.9	-1.0	-1.1	-1.3	-1.3
7Hz	-0.6	-0.7	-0.3	-0.9	-0.9	-0.9	-0.6	-0.7	-0.7	-0.7	-0.3	-0.7	-0.8	-0.8	-0.7	-0.7	-0.9	-1.0	-1.0
8Hz	0.1	0.2	0.2	0.0	0.1	0.1	0.4	-0.0	0.0	-0.2	0.6	-0.1	-0.5	-0.5	-0.5	-0.6	-0.8	-0.8	-0.8
9Hz	0.1	0.2	0.4	0.2	0.1	0.1	0.3	-0.0	-0.1	-0.2	1.0	0.1	-0.6	-0.8	-0.8	-0.8	-0.7	-1.0	-0.8
10Hz	0.0	0.1	0.2	0.1	0.1	0.1	0.0	-0.0	0.0	-0.1	0.7	-0.0	-0.2	-0.3	-0.3	-0.4	-0.4	-0.7	-0.6
11Hz	1.1	1.0	1.2	1.1	1.0	0.9	0.7	0.8	1.1	0.7	1.3	0.4	0.8	0.8	0.9	0.5	0.6	0.0	0.0
12Hz	0.7	0.7	0.8	0.8	0.7	0.6	0.5	0.7	0.8	0.5	1.0	0.1	0.6	0.2	-0.1	-0.0	0.0	-0.5	-0.6
13Hz	0.3	0.4	0.3	0.2	0.2	0.3	0.1	0.5	0.5	0.3	0.5	-0.3	0.3	0.3	-0.2	-0.3	-0.5	-0.6	-1.0
14Hz	0.3	0.3	0.4	0.3	0.3	0.2	-0.0	0.6	0.7	0.4	0.4	-0.4	-0.1	0.3	0.2	-0.0	-0.5	-0.6	-0.8
15Hz	0.0	0.0	0.2	0.0	-0.1	-0.2	-0.4	0.3	0.3	0.1	0.2	-0.7	-0.2	0.1	0.1	-0.1	-0.6	-0.7	-0.8
16Hz	-0.0	0.0	0.0	-0.1	-0.2	-0.2	-0.3	0.1	0.1	0.1	0.0	-0.7	-0.4	-0.0	-0.1	-0.3	-0.6	-0.7	-0.9
17Hz	-0.6	-0.5	-0.4	-0.6	-0.6	-0.7	-0.8	-0.0	-0.1	-0.1	-0.3	-0.9	-0.7	-0.2	-0.3	-0.4	-0.8	-1.0	-1.2
18Hz	-0.7	-0.6	-0.7	-0.9	-0.9	-1.0	-1.1	-0.2	-0.3	-0.5	-0.6	-1.1	-1.1	-0.5	-0.5	-0.6	-1.1	-1.3	-1.3
19Hz	-0.8	-0.7	-1.0	-1.2	-1.1	-1.1	-1.1	-0.5	-0.5	-0.7	-0.9	-1.2	-1.4	-0.9	-0.7	-0.9	-1.5	-1.6	-1.5
20Hz	-0.7	-0.6	-0.7	-1.1	-1.1	-1.1	-1.0	-0.6	-0.8	-1.0	-0.9	-1.3	-1.5	-0.9	-0.8	-1.0	-1.5	-1.6	-1.5
21Hz	-0.8	-0.7	-0.7	-0.8	-0.9	-0.9	-1.0	-0.5	-0.6	-0.9	-0.8	-1.2	-1.4	-0.8	-0.6	-0.8	-1.3	-1.5	-1.4
22Hz	-0.7	-0.6	-0.6	-0.8	-0.8	-0.8	-0.8	-0.6	-0.7	-0.7	-0.7	-1.0	-1.1	-0.5	-0.4	-0.5	-1.3	-1.4	-1.4
23Hz	-0.5	-0.4	-0.5	-0.6	-0.7	-0.8	-0.8	-0.6	-0.6	-1.0	-0.8	-1.1	-1.5	-0.7	-0.6	-1.1	-1.9	-1.8	-1.7
24Hz	-0.5	-0.4	-0.7	-0.8	-1.0	-1.0	-0.8	-0.8	-0.9	-1.2	-0.8	-1.0	-2.0	-1.1	-1.1	-1.4	-2.2	-2.1	-1.6
25Hz	-0.7	-0.7	-0.9	-0.7	-0.9	-1.0	-0.8	-0.9	-0.8	-1.2	-1.0	-0.9	-2.0	-1.2	-1.2	-1.6	-2.4	-1.9	-1.5
26Hz	-0.8	-0.7	-0.9	-0.9	-1.1	-1.1	-0.8	-1.2	-1.1	-1.3	-1.1	-0.9	-2.3	-1.5	-1.3	-1.8	-2.4	-2.0	-1.6
27Hz	-0.6	-0.6	-0.6	-0.8	-1.0	-1.0	-0.7	-1.3	-1.1	-1.3	-1.0	-0.8	-2.0	-1.4	-1.4	-2.0	-2.4	-2.0	-1.6
28Hz	-0.6	-0.6	-0.6	-0.8	-0.8	-0.9	-0.6	-1.3	-0.9	-1.3	-1.0	-0.8	-1.8	-1.5	-1.6	-2.0	-2.4	-2.2	-1.6
29Hz	-0.6	-0.6	-0.5	-0.7	-0.8	-0.9	-0.6	-1.2	-0.8	-1.2	-1.1	-0.8	-2.1	-1.5	-1.4	-1.8	-2.1	-2.2	-1.5
30Hz	-0.6	-0.5	-0.5	-0.6	-0.7	-0.7	-0.4	-1.2	-0.5	-1.0	-1.1	-0.8	-2.3	-1.7	-1.5	-1.8	-2.1	-2.0	-1.5

Areas govern:
 performing creative tasks, integer calculation;
 working/episodic memory, visuo-motor attention, auditory, gesture imitation, language, motor, pain, object and face perception, touch, balance

(L) axial (R) (L) coronal (R) (P) sagittal (A)



23-24 Hz

Other Substance Effect

- Lithium - Generalized Slowing
- Lead –
 - Acute - looks like diffuse encephalopathy
 - Chronic – Inconclusive
- Mercury
 - Nonspecific diffuse slowing reflecting clinical state
- Manganese
 - EEG slowing and fast activity
- Organophosphates
 - Slow wave enhancement, paroxysmal discharges

Toxomics meets
Connectomics

Mold and the Brain

- Measures of toxic mold exposure predicted QEEG measures and neuropsych test performance
 - Impairments similar to mild Traumatic Brain Injury
 - Multiple Cognitive task impairment
- QEEG=
 - Narrowed frequency bands
 - Increased Alpha and Theta frontally
 - Hypoactivation of the cortex
 - Due to Brainstem or Reticular Activating System Dysfunction?

Toxomics meets
Connectomics

Severe MDD, Elevated Lead

02-2011

Severe, Chronic Depression.
Past Tx: Prozac, Zoloft, Celexa,
Wellbutrin, Paxil, Effexor,
Geodon, Cymbalta, Seroquel,
Xanax, Klonopin, Adderall,
Nuvigil, Provigil, ECT x3.

Of note, pt was
infertile, and
thought herself
unfit to be a
mother.



Found to have
elevated lead on
challenge testing.

Underwent QEEG
guided
Neurofeedback
using Z-score 3D
training settings.
Gut Repair, DMSA
Chelation



7-2011

Marked improvement on EEG
and symptoms.



2-2012


“No Depression” Starting career.
Changing Family Dynamics



**2015- My Patient
and her **SECOND**
child. 😊**

**Functional
Medicine Changes
Lives**

Digging Deeper in Assessment



Deep Data meets Big Data



Leaves, Trees and
Forrests..